Nucleophosmin (NPM1) mutations represent one of the most frequently identified genetic alterations in acute myeloid leukemia, occurring in approximately 30 to 35 percent of newly diagnosed cases.1
The prognostic significance of NPM1 mutations is context-dependent. In isolation or with certain low-risk co-mutations, NPM1-mutated AML carries a relatively favorable prognosis. However, concurrent FLT3-ITD mutations can attenuate this benefit.2 Interaction between NPM1 and FLT3 mutation status has informed risk stratification and influenced recommendations regarding allogeneic stem cell transplantation in first remission.2
Beyond prognosis, NPM1 mutations serve as accessible disease biomarkers. Their stability makes them well-suited for measurable residual disease monitoring via molecular methods.3 Sensitive detection identifies subclinical disease and increasing mutation burden following treatment correlates with higher relapse risk, informing surveillance strategies. The role of pretransplant MRD status in guiding allogeneic stem cell transplantation decisions continues to evolve, with emerging evidence suggesting that molecular disease detection at transplant may not uniformly predict adverse posttransplant outcomes in this subtype.4
The biology extends beyond the mutation itself to encompass characteristic gene expression profiles and epigenetic landscapes. NPM1-mutated cases often demonstrate specific patterns of HOX gene dysregulation and DNA methylation changes, suggesting potential therapeutic vulnerabilities.3 In relapsed or refractory settings, NPM1-mutated AML presents challenges and opportunities. Standard salvage regimens achieve variable response rates based on remission duration, prior therapy, and patient fitness. Menin inhibitors have demonstrated activity in AML driven by aberrant HOX gene expression, including NPM1-mutated and KMT2A-rearranged subtypes, while immunotherapy approaches directed against NPM1-specific neoantigens are in early-stage investigation.5,6
Treatment selection requires consideration of fitness for intensive therapy, remission duration, and actionable co-mutations. While NPM1 status alone may not direct therapy choice, the broader molecular context, including FLT3, IDH1, or IDH2 co-mutations, can identify patients who may benefit from targeted agents, including post-remission maintenance approaches in select cases.7 Recognition of NPM1-mutated AML as a distinct biological entity has refined approaches to classification and stratification, with routine testing remaining essential in contemporary management.
Take our acute myeloid leukemia quiz to see how your knowledge compares to your peers.
